The global antipsychotic drugs market size is calculated at USD 19.61 billion in 2025 and is forecasted to reach around USD 33.09 billion by 2034, accelerating at a CAGR of 5.99% from 2025 to 2034. The North America antipsychotic drugs market size surpassed USD 9.80 billion in 2024 and is expanding at a CAGR of 6.09% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antipsychotic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antipsychotic Drugs Market, by Therapeutic Class
8.1.1. First Generation
8.1.1.1. Market Revenue and Forecast
8.1.2. Second Generation
8.1.2.1. Market Revenue and Forecast
8.1.3. Third Generation
8.1.3.1. Market Revenue and Forecast
9.1. Antipsychotic Drugs Market, by Disease
9.1.1. Schizophrenia
9.1.1.1. Market Revenue and Forecast
9.1.2. Bipolar Disorder
9.1.2.1. Market Revenue and Forecast
9.1.3. Unipolar Depression
9.1.3.1. Market Revenue and Forecast
9.1.4. Dementia
9.1.4.1. Market Revenue and Forecast
9.1.5. Other Diseases
9.1.5.1. Market Revenue and Forecast
10.1. Antipsychotic Drugs Market, by Drug
10.1.1. Risperidone
10.1.1.1. Market Revenue and Forecast
10.1.2. Quetiapine
10.1.2.1. Market Revenue and Forecast
10.1.3. Olanzapine
10.1.3.1. Market Revenue and Forecast
10.1.4. Aripiprazole
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Antipsychotic Drugs Market, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Drug Stores & Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutic Class
12.1.2. Market Revenue and Forecast, by Disease
12.1.3. Market Revenue and Forecast, by Drug
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutic Class
12.1.5.2. Market Revenue and Forecast, by Disease
12.1.5.3. Market Revenue and Forecast, by Drug
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutic Class
12.1.6.2. Market Revenue and Forecast, by Disease
12.1.6.3. Market Revenue and Forecast, by Drug
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutic Class
12.2.2. Market Revenue and Forecast, by Disease
12.2.3. Market Revenue and Forecast, by Drug
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutic Class
12.2.5.2. Market Revenue and Forecast, by Disease
12.2.5.3. Market Revenue and Forecast, by Drug
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutic Class
12.2.6.2. Market Revenue and Forecast, by Disease
12.2.6.3. Market Revenue and Forecast, by Drug
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutic Class
12.2.7.2. Market Revenue and Forecast, by Disease
12.2.7.3. Market Revenue and Forecast, by Drug
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutic Class
12.2.8.2. Market Revenue and Forecast, by Disease
12.2.8.3. Market Revenue and Forecast, by Drug
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutic Class
12.3.2. Market Revenue and Forecast, by Disease
12.3.3. Market Revenue and Forecast, by Drug
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutic Class
12.3.5.2. Market Revenue and Forecast, by Disease
12.3.5.3. Market Revenue and Forecast, by Drug
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutic Class
12.3.6.2. Market Revenue and Forecast, by Disease
12.3.6.3. Market Revenue and Forecast, by Drug
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutic Class
12.3.7.2. Market Revenue and Forecast, by Disease
12.3.7.3. Market Revenue and Forecast, by Drug
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutic Class
12.3.8.2. Market Revenue and Forecast, by Disease
12.3.8.3. Market Revenue and Forecast, by Drug
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutic Class
12.4.2. Market Revenue and Forecast, by Disease
12.4.3. Market Revenue and Forecast, by Drug
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutic Class
12.4.5.2. Market Revenue and Forecast, by Disease
12.4.5.3. Market Revenue and Forecast, by Drug
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutic Class
12.4.6.2. Market Revenue and Forecast, by Disease
12.4.6.3. Market Revenue and Forecast, by Drug
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutic Class
12.4.7.2. Market Revenue and Forecast, by Disease
12.4.7.3. Market Revenue and Forecast, by Drug
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutic Class
12.4.8.2. Market Revenue and Forecast, by Disease
12.4.8.3. Market Revenue and Forecast, by Drug
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutic Class
12.5.2. Market Revenue and Forecast, by Disease
12.5.3. Market Revenue and Forecast, by Drug
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutic Class
12.5.5.2. Market Revenue and Forecast, by Disease
12.5.5.3. Market Revenue and Forecast, by Drug
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutic Class
12.5.6.2. Market Revenue and Forecast, by Disease
12.5.6.3. Market Revenue and Forecast, by Drug
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Johnson & Johnson
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Otsuka Pharmaceutical Co, Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AbbVie Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bristol-Myers Squibb
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teva Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Dr. Reddy's Laboratories
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample